Navigation Links
New Anti-Clotting Treatment Urged for Cancer Patients
Date:2/13/2009

Warfarin failed to reduce catheter-related clots, study finds,,

FRIDAY, Feb. 13 (HealthDay News) -- The blood thinner warfarin does not reduce catheter-related blood clots in cancer patients, so new treatments are needed to prevent this complication, says a U.K. study.

About 50 percent of cancer patients develop venous thromboembolism, which can be caused by a number of factors, including the use of central venous catheters to deliver infusional chemotherapy, according to background information in the study. The use of warfarin with the catheters to prevent clotting is controversial because there's no clear evidence that it's effective.

The study included 1,590 cancer patients at 68 centers who were receiving chemotherapy through central venous catheters. The patients were randomly selected to receive either no warfarin, a fixed dose of 1 milligram of warfarin a day or dose-adjusted warfarin daily.

Overall, rates of catheter-related blood clots were the same (6 percent) whether people were or were not given warfarin. Those who received dose-adjusted warfarin did have fewer blood clots than those given the fixed dose (3 percent vs. 7 percent), but there were more occurrences of major bleeding in the dose-adjusted group (16 vs. 7).

The study was published in this week's edition of The Lancet.

"The rate of symptomatic catheter-related thromboses reported in clinical trials has fallen substantially over the past decade," wrote Annie Young and colleagues from the Institute for Cancer Studies at the University of Birmingham. "The improvements in catheter technology, placement and aftercare are contributing to this reduction. When any benefit of thromboprophylaxis (treatment to prevent blood clots) was balanced against the risk of major bleeding, the combined outcome showed no advantage with the use of any dose of warfarin."

"These findings only add to the assertion that the time has come to move on from warfarin for thromboprophylaxis in patients with cancer," they wrote. "We should consider new treatments."

Dr. Paolo Prandoni, of the University of Padua in Italy, wrote in an accompanying editorial that though there's no evidence that warfarin helps prevent catheter-related blood clots in cancer patients, doctors should make an effort to identify people at highest risk of clotting because they might benefit most from anti-clotting treatment.

More information

The American Society of Clinical Oncology has more about preventing and treating blood clots.



-- Robert Preidt



SOURCE: The Lancet, news release, Feb. 12, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Anti-Clotting Drug as Good as Aspirin at Stopping Second Stroke
2. Anti-Clotting Drug Helps Infants With Heart Ills
3. Anti-Clotting Drug Trial Shortened by Bleeding Problems
4. Researchers identify molecules with interesting anti-clotting properties
5. New Anti-Clotting Drug Shows Promise in Heart Patients
6. Possible safer target for anti-clotting drugs found
7. New Anxiety and Mood Disorders Intensive Treatment Program in Downtown Chicago
8. Free Community Seminar to Review Treatment Options for Enlarged Prostate
9. TV News Coverage Reports on InnerCools CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago
10. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
11. Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Anti-Clotting Treatment Urged for Cancer Patients
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: